Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195878 | 1.00 | NR3C1 (0.54) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4201035 | 0.91 | NR3C1 (0.58) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4195766 | 0.90 | HTR2C (0.53) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4195759 | 0.90 | HTR2C (0.53) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4206291 | 0.90 | HTR2C (0.53) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4202815 | 0.82 | HTR2C (0.45) | HTR6LMNAHTR2CMAPT | |
| SCHEMBL4202820 | 0.82 | HTR2C (0.45) | HTR6LMNAHTR2CMAPT | |
| SCHEMBL4204724 | 0.81 | TSHR (0.55) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL4193701 | 0.77 | NR3C1 (0.53) | NR3C1PGRARESR2HDAC1 | |
| SCHEMBL1546446 | 0.76 | DRD2 (0.60) | HDAC1HDAC8HTR6LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | NR3C1 120/4885PGR 492/4885AR 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.